The United Kingdom and the United States have agreed to a landmark commercial pact that will maintain no tariffs on British medicine exports going into the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the public health system. This commitment guarantees that import taxes on these vital exports will remain at nothing for a duration of 36 months.
This deal is in response to earlier warnings to significantly raise tariffs on branded pharmaceutical imports, with figures discussed reaching double the cost.
"This agreement with the United Kingdom strengthens the worldwide climate for new treatments and brings much-needed fairness to American-British medicine commerce," an announcement noted.
Trade Impact
Pharmaceuticals are one of the the United Kingdom's largest export categories to the America, which is by far the biggest market for major UK drugmakers.
Export figures show that in the 12 months leading up to last September, the UK exported medicines worth billions to the US. This figure made up nearly one-fifth of all goods exports in that period.
"This guarantee protects work, stimulates investment and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement includes several specific pledges from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to increase total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded 20%.
Industry Background
This agreement follows a long-running dispute between the drug companies and the ministers over spending levels and regulatory access.
This friction were heightened by claims that US consumers were charged a premium for the equivalent treatments than consumers in the other developed nations.
In recent months, several major drug company projects in the UK have been paused or scrapped, while major investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had decreased as a share of its total funding over the last ten years.
